An operation that targets the nerves connected to the kidney has been found to significantly reduce blood pressure in patients with hypertension, according to the results of a clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust, and supported by the National Institute for Health Research (NIHR).
If the findings are confirmed in more extensive clinical trials, the surgery could offer hope to patients with high blood pressure who do not respond to drugs, and are at increased risk of cardiovascular diseases, including stroke and heart attack.
The international clinical trial, carried out from 2017 to 2018 at St Bartholomew’s Hospital in the UK by the NIHRBarts Biomedical Research Centre, tested a one-hour operation called ‘renal denervation’, which uses ultrasound energy to disrupt the nerves between the kidneys and the brain that carry signals for controlling blood pressure.
Significant reduction in blood pressure
146 patients in the United States, France, Germany, the Netherlands, Belgium and the United Kingdom were randomised to receive either renal denervation or a ‘sham procedure’ – the surgical equivalent of a placebo. Patients also remained off blood pressure medications for two months unless specified blood pressure levels were exceeded.
After two months, the renal denervation group experienced an 8.5 mm Hg reduction in blood pressure, which was a 6.3 mm Hg greater reduction compared with the sham group.
More than 66 per cent of subjects treated with renal denervation demonstrated a 5 mm Hg or greater reduction in blood pressure, compared with 33 per cent in the sham group.
No major adverse events were reported in either group, and the blood pressure lowering effect of renal denervation was consistent across sex and ethnicity.
An alternative to lifelong medications
UK Principal Investigator Dr Melvin Lobo from Queen Mary’s William Harvey Research Institute and Barts Health NHS Trust said: “These results leave us clinicians in no doubt that this ultrasound-based therapy works to improve blood pressure control – at least in the short term. Further larger trials will be needed to confirm the efficacy and safety of the technology, but we hope that they could lead to renal denervation therapy being offered as an alternative to lifelong medications for hypertension.”
The study has limitations including the short follow-up time of two months. This was done for safety reasons to minimise the duration of patients being off antihypertensive medications. Longer follow-up of this trial and additional numbers of treated patients will be necessary to provide greater assurance of safety and to exclude rare adverse events.
The Latest on: Hypertension
via Google News
The Latest on: Hypertension
- Liminal Presents New Preclinical Data on PBI-4050 and its Effect on Angio-Proliferative Pulmonary Arterial Hypertensionon November 19, 2019 at 8:18 am
Key data was presented at the conference in two poster presentations entitled: PBI-4050 Reduces Angio-proliferative Pulmonary Arterial Hypertension: Decreased Human Pulmonary Artery Smooth Muscle Cell ...
- Hypertension associated with Indian ethnicity and diabeteson November 18, 2019 at 10:44 pm
Hypertension, or high blood pressure, often goes hand in hand with diabetes. This doesn’t come as a surprise anymore, especially if you consider that both ailments are, by their very nature, more ...
- Four-year adiposity change and remission of hypertension: an observational evaluation from the Longitudinal Study of Adult Health (ELSA-Brasil)on November 18, 2019 at 4:57 am
The degree to which weight reduction leads to the remission of hypertension in population studies is not clear. We investigated whether the changes in adiposity measures predicted the remission of ...
- Hypertension treatment tied to lower risk for Dementia, Alzheimer’son November 16, 2019 at 11:12 am
During a median follow-up of 7 to 22 years, roughly 3,700 developed dementia, nearly half of whom developed Alzheimer disease. Among participants with hypertension, those who used any antihypertensive ...
- Pulmonary arterial hypertension targeted for new treatmenton November 15, 2019 at 7:04 am
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new ...
- A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertensionon November 15, 2019 at 2:21 am
Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Current treatments increase life expectancy but have limited impact on the progressive pulmonary vascular remodelling that drives PAH ...
- Is there a link between diabetes and hypertension?on November 14, 2019 at 1:02 am
Whether it’s type 1 or 2, diabetes mellitus shares a number of risk factors with high blood pressure (BP), or hypertension, such as obesity, inactivity, older age and hormonal imbalance. Dr Igbal ...
- Knowing the facts: Hypertension vis-a-vis Lifestyleon November 13, 2019 at 10:29 pm
High blood pressure, or hypertension, is commonly referred to as a ‘silent killer’. This is mainly because it rarely presents warning signs at its onset, considerably delaying diagnosis and treatment.
- Global Hypertension Drug Market Growth To Be Driven By The Increasing Hospital and Private clinic Across The Globeon November 13, 2019 at 2:36 am
Nov 13, 2019 (WiredRelease via COMTEX) -- The industry analysis report identifying hidden opportunities of Hypertension Drug Market, which will help to expand operations in the existing markets. The ...
via Bing News